Dr. MingXi Li serves as Partner at GT Healthcare Capital Partners. Experienced with identifying innovative technologies and commercializing them, MingXi is a US trained professional focusing on life science sector with keen understanding of global and China healthcare market. He has established a track record of investing in China as well as cross-border transactions, and stayed well connected with industrial leaders, entrepreneurs, investors and academia in both China and US. MingXi serves on the board of a number of prominent pharmaceutical and diagnostic companies in China as well. He was Senior Director at Simcere Pharmaceutical Group from 2013 to 2017, and managed Simcere’s portfolio of investments (>150M USD) in various venture funds, including Cormorant Asset Management (MA, USA), Ally Bridge Group (HK), Partners Innovation Fund (MA, USA), PointGuard Ventures (CA, USA), Bohe Angels (Suzhou, China) and Tenyall Capital (Nanjing, China). He also served on the investment committee of Tenyall Capital. MingXi graduated with a B.S. in Biological Science and Biotechnology from Tsinghua University and has a Ph.D. in Biochemistry from University of Illinois at Urbana-Champaign. Earlier in his career, he worked in Jiuding Capital, covering Chinese pharma/IVD/hospital sectors, and later at Simcere Pharma/Bioscikin covering clinical and pre-clinical stage biopharma investments globally.